Regeneron Pharmaceuticals (REGN) revenue breakdown
By product, Collaboration revenue is the largest at 51% of fiscal 2025 revenue, growing 44% a year over 5 years.
Revenue by product
Fiscal years, as Regeneron Pharmaceuticals reports them in its 10-K filings; fiscal 2025 total $14.3B.
| Products | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|
| Collaboration revenue | $1.2B | $3.7B | $4.9B | $5.5B | $6.1B | $7.3B | 51% |
| Net product sales | $5.6B | $12.1B | $6.9B | $7.1B | $7.6B | $6.3B | 44% |
| Other revenue | $557M | $281M | $365M | $536M | $515M | $703M | 5% |
| Sanofi collaboration revenue | $1.2B | — | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for REGN.
Open REGN in InvestinglyQuestions
Where does Regeneron Pharmaceuticals make its money?
In fiscal 2025, by product: Collaboration revenue $7.3B, Net product sales $6.3B, Other revenue $703M.
From Regeneron Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.